Immune cells engineered to hunt cancer: new trial for hard-to-treat blood cancers

NCT ID NCT06696846

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new cell therapy for people with T-cell lymphoma or acute myeloid leukemia that has come back or not responded to standard treatments. The therapy uses immune cells (NK cells) from donated cord blood that are engineered to recognize and attack cancer cells carrying a protein called CD70. The main goals are to check safety and see if the treatment shrinks tumors or clears leukemia from the bone marrow.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia T-cell non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA RELAPSED/REFRACTORY T-CELL LYMPHOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310009, China

Contact Phone: •••-•••-•••• Email: •••••@•••••